BlackRock, Inc. 13D and 13G filings for Eagle Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 351,570 2.700% | -632,505 (-64.27%) | Filing |
| 2024-01-26 11:49 am Sale | 2023-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 984,075 7.600% | -25,015 (-2.48%) | Filing |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 1,009,090 7.700% | -863,811 (-46.12%) | Filing |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 1,872,901 14.400% | 0 (Unchanged) | Filing |
| 2023-01-20 3:00 pm Sale | 2022-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 1,872,901 14.400% | -95,915 (-4.87%) | Filing |
| 2022-01-27 11:00 am Unchanged | 2021-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 1,968,816 15.200% | 0 (Unchanged) | Filing |
| 2022-01-25 3:03 pm Purchase | 2021-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 1,968,816 15.200% | 27,800 (+1.43%) | Filing |
| 2021-01-26 2:22 pm Purchase | 2020-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | BlackRock Inc. BLK | 1,941,016 14.900% | 132,504 (+7.33%) | Filing |